Important Notice The purpose of the presentation is to provide an update of the business of Prima BioMed Ltd ACN 009 237 889 (ASX:PRR). These slides have been prepared as a presentation aid only and the information they

Ian Frazer Prof. Neil Foster developing dense gas technology to formulate oral HPV vaccine Program Status Studies with Eudragit coated lyzosyme completed feasibility studies with ovalbumin ongoing Animal studies initiated to evaluate immunogenicity 21 Financial Profile Financial Profile ASX Code PRR (Australian Security) NASDAQ Code PBMD(ADR Lvl 2 30:1) Shares 1,065 million Price Capitalization Price Capitalization Share Price $0.24 (16/3/12) 2011 high $0.42 (4/11/11) Market Cap $255 million (as of March 2012) Cash Position $47.5 million (as of December 31, 2011) Figures In AUD$ Financial Profile Price Capitalisation Prima BioMed: Strategically Positioned Develop and commercialize new therapies to address unmet medical needs primarily in oncology CVac has potential to transform treatment of ovarian cancer in remission Pivotal study has been designed to seek global registration in key markets including U.S. and EU First company potentially with a dendritic cell based therapy drug in the EU Granted marketing distribution approval in the Dubai Healthcare City Potential to treat other mucin 1 over expressing tumours eg breast, colorectal, lung, gastric pancreatic cancers Pursue best value for shareholders in commercializing CVac globally Pilot commercialisation in Dubai will lead the way Other products in development pipeline at earlier stages of development Oral HPV vaccine created using dense gas technology Humanized monoclonal antibody targeting Cripto 1 22 The Cutting Edge in the Fight Against Cancer Investor Presentation April 2012 23 Martin Rogers Chief Executive Officer

Next steps Preclinical studies underway to determine whether the human versions of the rat antibodies can cause apoptosis in a similar manner Studies designed to support an Initial New Drug (IND) application in human trials in 2013 18 19 Oral HPV Vaccin e Driving Differentiation with Science: Oral HPV Vaccin e Developing technology to enable oral administration of vaccines that are currently injected Reformulate large, irregular particles into smaller consistent sizes allowing higher bioavailability of lower doses in an oral formulation Lead target is an oral vaccine against Human Papilloma Virus (HPV) associated with development of cervical cancer Ongoing collaborative venture with the University of New South Wales and University of Queensland 20 Prof.

Australia to: Assure comparability of multiple manufacturing centers Confirm safety tolerability established in earlier trials Compare CVac to standard of care (progression free survival) Confirm host immunologic response to CVac therapy Recruitment completed in September 2011 Interim PFS Data in 2012 Final PFS Data anticipated in 2013 14 st nd CVac: Pivotal (CANVAS) Study Design CANVAS( cer ccine tudy) is multinational, multi centre, randomized, double blinded, placebo controlled 800 patients randomized, double blinded, well designed efficacy trial Definitively establish survival benefit progression free survival (PFS) overall survival (OS) Assess quality of life pharmacoeconomic parameters Support marketing authorizations globally ~150 centers, 22 countries U.S., Australia Europe Based on expected recruitment rates, full patient enrollment by ~2H 2013* 15 *CANVAS is event driven study actual study timelines dependent on patient outcomes in trial CAN VA S Potential maintenance treatment for epithelial ovarian, primary peritoneal or fallopian tube cancer in complete remission CVac: Assessing Global Market Potential 16 SIGNIFICANT MARKET OPPORTUNITY Multi billion dollar ovarian cancer treatment vaccine market Global market size is estimated to be $3.6 billion First to market maintenance therapy has potential to achieve 10% of market in first year of launch 10% of market may capture $500 million+ in sales throughout the developed world 17 Anti Cripto 1 Ma b Driving Differentiation with Science: Anti Cripto 1 Ma b Identification and development of a monoclonal antibody to Cripto 1 Protein found in high levels on the surface of many tumors Neutralizing the Cripto 1 protein may enable targeting of multiple tumor types (breast, colon, lung, stomach pancreas) Effects of Cripto 1 Mab were greater in presence of cytotoxic drugs such as 5 fluorouracil, epirubicin cisplatin Injection of these antibodies into mice has been able to both prevent tumor growth and eradicate existing tumors by inducing apoptosis.

FDA EMA Additional several years of exclusivity and priority regulatory treatment Phase I Phase IIa trials are complete with promising results 7 CVac: Program Overview (Con t.) CVac granted marketing distribution approval in the Dubai Healthcare City First sales expected in 2012 Pilot scale commercialisation program Generates revenue in growing Middle Eastern healthcare market Manufacturing authorization in place and ready to go US partner, NeoStem (Progenitor Cell Therapies) EU partner, Fraunhofer Institute for Cell Therapy Immunology Australian partner, Cell Therapies/ Peter MacCallum Cancer Centre Market exclusivity with broad IP position and strategy Issued patents extend to 2023/2024 Biologic difficult to replicate Granted Orphan Drug Designation by FDA and EMA 8 CVac: Unique Mechanism of Action 9 CVac: Basis for Maintenance Therapy in Ovarian Cancer 10 Unmet medical need in ovarian cancer 73,000 women diagnosed each year in the U.S., EU, Australian and Japan 318,000 women diagnosed globally Generally diagnosed at late stage Only 20 30% of patients with late stage disease survive 5 years Median progression free survival after optimal surgery chemotherapy is only 22 months Reference: Thomson Business intelligence, Ovarian Cancer Therapeutics Industry Analysis 2007 CVac: Evidence of Clinical Activity Phase Ib Study Design 14 patients with terminal cancer (3 6 months life expectancy), broad range of adenocarcinomas including renal, breast, ovarian, fallopian tube, colon, lung esophageal Objectives: Primary endpoint: safety and assess toxicity Secondary endpoint: assess anti tumor efficacy, immune response procedure feasibility Clinical Trial Results 13 evaluable patients, 5 had stable disease during the assessment period of 1 year 2 patients received ongoing therapy for 40mths First time that every patient had immune responses All patients produced desired cellular immune responses No treatment related toxicity Patients cells successfully cryo preserved 11 CVac: Ovarian Tumours Respond to Therapy with CA125 Reduction Phase IIa Study Design(n=28) Patients received 3 CVac injections over 10 weeks, followed by 4 injections at 10 week intervals 21 evaluable with incurable ovarian cancer rising CA125 levels at least 25% over baseline within 28 days multiple courses of chemotherapy/ radiotherapy Objectives Primary endpoint: CA125 response or stabilization in at least 15% patients Secondary endpoint: Disease progression free survival, immune response safety Clinical Trial Results 19% (4 of 21) of patients responded to therapy (CA 125 reduction) Progression free survival averaged 127 days (95% confidence limits 96 219 days) Median survival was 219 days (95% Confidence Limits 175 409 days) Importantly no drug related toxicity 12 Treating Stage III Ovarian Cancer Patient Stable disease 4mths 18mths 13 CVac treatment demonstrates stabilization of CA125 initially for 4mths, then for Incurable recurrent disease, diagnosed by elevated CA125 marker Low 5 year survival rate and late stage detection further 18mths post further injections of CVac CVac: Targeting Ovarian Cancer Phase I and IIa trials indicate CVac could be strong candidate for treating ovarian cancer patients in remission for other MUC 1 over expressing tumors Phase IIb trial (63 patients) for ovarian cancer patients after successful 1 or 2 line therapy has completed recruiting patients in U.S.

Neil Frazer Chief Medical Officer 25+ years clinical trials Formerly with Glaxo 10 FDA approvals Ian Bangs Chief Financial Officer Corporate Secretary Experienced public/private companies for 25+ years Marc Voigt General Manager European Op. SVP BD Extensive Experience in the Corporate Biotech VC and Biotechnology Sector Dr. Sharron Gargosky Senior Vice President CVac 17 + years experience with orphan drug approvals Marta Schilling Vice President Manufacturing 20+ years experience in CMC/QA and cell therapies CVac Targeting Ovarian Cancer 6 CVac: Program Overview CVac is an autologous, dendritic cell based therapy or cancer vaccine Proven technology with FDA approval of Provenge Progressing clinical studies of the first ovarian cancer therapeutic vaccine Upcoming pivotal (CANVAS) and ongoing Phase IIb trials to provide further proof of concept for global registration Granted orphan drug status by the U.S.

This presentation should not be relied on as a recommendation or forecast by Prima BioMed Limited. Nothing in this presentation should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction. 2 Prima BioMed: An Emerging Presence in Oncology Prima BioMed is a biotechnology company focused on developing novel oncology therapies in the field of immunotherapy and immunology Prima BioMed has a clear strategy to develop and commercialize therapeutic vaccine CVac in ovarian The Company is listed on the Australian Stock Exchange (NASDAQ:PBMD) 3 cancer with an opportunity to expand to other indications (ASX:PRR) and NASDAQ under the symbols TM Prima BioMed Investment Overview Leadership in emerging immunotherapy arena with CVac poised to commence pivotal clinical trials in the U.S., EU and Australia Focused on major markets with unmet medical needs and limited competition Broad intellectual property position Potential to leverage future development opportunities Management team with a proven development and commercial track record in oncology Solid and disciplined financial position Significant near term and long term catalysts 4 Prima BioMed: Introduction Leadership Team 5 Extensive business management experience scientific background Martin Rogers Managing Director and Chief Executive Officer Mathew Lehman Chief Operating Officer Experience in execution of over 100 clinical trials in EU US Dr.

Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation include known and unknown risks. Because actual results could differ materially to assumptions made and Prima BioMed s current intentions, plans, expectations and beliefs about the future, you are urged to view all forward looking statements contained in this presentation with caution.

No representation or warranty is made as to the accuracy, completeness or reliability of the information. Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside Prima BioMed Ltd s control.

Accordingly, these slides and the information they contain should be read in conjunction with past and future announcements made by Prima BioMed and should not be relied upon as an independent source of information. Please contact Prima BioMed and/or refer to the Company's website for further information. The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified.

The Cutting Edge in the Fight Against Cancer Investor Presentation April 2012 Martin Rogers Chief Executive Officer (ASX:PRR, NASDAQ:PBMD) Exhibit 99.1 Important Notice The purpose of the presentation is to provide an update of the business of Prima BioMed Ltd ACN 009 237 889 (ASX:PRR). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification.